trending Market Intelligence /marketintelligence/en/news-insights/trending/XLMf0B2X-IgOouvJA2e7LA2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Emergent wins approval to sell typhoid vaccine in 5 more EU countries

Blog

Global M&A Infographic Q1 2021

Blog

Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge

Blog

COVID-19 Impact & Recovery: Private Equity

COVID-19 Impact & Recovery: Corporates


Emergent wins approval to sell typhoid vaccine in 5 more EU countries

Emergent BioSolutions Inc. secured approval to sell its typhoid fever vaccine in five additional European Union member states — France, Portugal, Poland, Czech Republic and Slovakia.

The company's Vivotif oral vaccine is used to prevent typhoid fever, a potentially severe and life-threatening infection caused by the bacterium Salmonella enterica serovar Typhi, in adults and children aged 5 and older.

The Gaithersburg, Md.-based biotech company is selling the drug under the name Vivotif in the U.S. and Europe and as Typhoral L in Germany.